Pages
Products
AAV9-CAG-NLuc-2A-GFP

AAV9-CAG-NLuc-2A-GFP

Cat.No. :  AAV00530Z

Titer: ≥1x10^12 GC/mL / ≥1x10^13 GC/mL Size: 30 ul/100 ul/500 ul/1 ml

Serotype:  AAV Serotype 9 Storage:  -80 ℃

Inquire for Price

AAV Particle Information

Quality Control

Cat. No. AAV00530Z
Description AAV serotype 9 particles express 2A-linked NanoLuc Luciferase and GFP reporter genes under the control of CAG promoter for neuronal specific expression.
Reporter GFP, NLuc
Serotype AAV Serotype 9
Target Gene NLuc-2A-GFP
Application

1. Determination of optimal MOI (multiplicity of infection), administration methods etc.

2. Detection of the infection efficiency of the AAV serotype against a specific cell type or tissue.

3. Using reporter genes to visualize the distribution and expression of AAV vectors in live animals, helping assess the biodistribution and persistence of gene delivery.

Titer Varies lot by lot, typically ≥1x10^12 GC/mL
Size Varies lot by lot, for example, 30 μL, 50 μL, 100 μL etc.
Storage Store at -80℃. Avoid multiple freeze/thaw cycles.
Shipping Frozen on dry ice
Creative Biogene ensures high-quality AAV particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between AAV particle lots.
Endotoxin Endotoxins, primarily derived from Gram-negative bacteria, can trigger adverse immune responses. Endotoxin contamination is a significant concern in the production of AAV, especially for applications in animal studies and gene therapy. Effective endotoxin quality control is essential in the development and manufacturing of AAV particles. Creative Biogene utilizes rigorous endotoxin detection methods to monitor the endotoxin level in our produced AAV particles to ensure regulatory compliance.
Purity AAV purity is critical for ensuring the safety and efficacy of AAV-based applications.AAV capsids are composed of three main protein components, known as viral proteins: VP1, VP2, and VP3. These proteins play a critical role in the structure and functionality of the AAV capsid. Monitoring the VP1, VP2, and VP3 content in AAV preparations is essential for quality control in AAV production. Our AAV particles are tested for showing three clear bands of VP1, VP2 VP3 by SDS-PAGE.
Sterility The AAV virus samples are inoculated into the cell culture medium for about 5 days to detect bacterial and fungal growth.
Transducibility Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of AAV to deliver genetic material into target cells or tissues, and assess gene expression and functional activities.
Empty vs. Full Capsids Based-on our proprietary AAV production and purification technology, Creative Biogene can always offer AAV particles with high ratio of full capsids. If required, we can also assess the ratio for a specifc lot of AAV particles by transmission electron microscopy (TEM) or other methods.
Quick Inquiry

Background

Publications

Q & A

Customer Reviews

AAV9-CAG-NLuc-2A-GFP is a cutting-edge adeno-associated virus serotype 9 (AAV9) vector designed for efficient expression of dual reporter genes in the nervous system. This vector offers several key advantages: 1) The CAG hybrid promoter (combining CMV enhancer and chicken β-actin promoter elements) ensures strong and widespread expression, particularly high efficiency in neuronal cells. 2) Compared to other serotypes, the AAV9 serotype exhibits superior central nervous system (CNS) targeting, higher blood-brain barrier penetration, and lower immunogenicity. 3) The bicistronic design incorporates a self-cleaving 2A peptide between the NanoLuc luciferase (NLuc) and GFP reporter genes, allowing simultaneous expression of both reporter genes from the same transcript while maintaining the correct expression ratio. 4) NanoLuc luciferase offers extremely high sensitivity (150 times brighter than firefly luciferase) and a broad linear dynamic range, suitable for quantitative analysis, while GFP facilitates visual tracking. 5) The vector maintains the characteristic safety profile of AAV, with stable episomal existence and low genotoxicity risk.

This dual-reporter AAV9 vector has broad applications in neuroscience research and therapeutic development. Its main applications include: 1) Long-term monitoring of neuronal transduction efficiency in vivo through non-invasive bioluminescence imaging (NLuc) combined with histological GFP localization. 2) Quantitative assessment of gene delivery optimization parameters (dose, administration route, time course) in CNS targeting studies. 3) Validation of AAV9-based gene therapy constructs through co-expression tracking. 4) Neural circuit mapping utilizing the retrograde transport properties of AAV9. 5) High-throughput screening of neuroprotective compounds by correlating luciferase activity with cell viability. 6) Validation of CRISPR editing or other genetic modifications using the dual reporter genes in neuronal cultures.
Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Customer Reviews
Great product!

The AAV9-CAG-NLuc-2A-GFP has proven to be extremely reliable for our long-term expression studies. Creative Biogene's product quality and consistency are second to none.

Germany

09/12/2022

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction